Homotype-Targeted Biogenic Nanoparticles to Kill Multidrug-Resistant Cancer Cells.
Imran Shair MohammadBirendra ChaurasiyaXuan YangChuchu LinHehui RongWei HePublished in: Pharmaceutics (2020)
"Off-targeting" and receptor density expressed at the target sites always compromise the efficacy of the nanoparticle-based drug delivery systems. In this study, we isolated different cell membranes and constructed cell membrane-cloaked biogenic nanoparticles for co-delivery of antitumor paclitaxel (PTX) and multidrug resistance (MDR)-modulator disulfiram (DSF). Consequently, MDR cancer cell membrane (A549/T)-coated hybrid nanoparticles (A549/T CM-HNPs) selectively recognized the source cells and increased the uptake by ninefold via the homotypic binding mechanism. Moreover, the A549/T CM-HNPs sensitized MDR cells to PTX by suppressing P-glycoprotein (P-gp) activity by 3.2-fold and induced effective apoptosis (70%) in homologous A549/T cells. Cell-membrane coating based on the "homotypic binding" is promising in terms of promoting the accumulation of chemotherapeutics in MDR cells and killing them.
Keyphrases
- multidrug resistant
- cell cycle arrest
- induced apoptosis
- endoplasmic reticulum stress
- drug resistant
- cell death
- gram negative
- acinetobacter baumannii
- pi k akt
- single cell
- squamous cell carcinoma
- binding protein
- cancer therapy
- wastewater treatment
- signaling pathway
- pseudomonas aeruginosa
- dna repair
- stem cells
- klebsiella pneumoniae
- mesenchymal stem cells
- cell therapy
- endothelial cells
- squamous cell
- lymph node metastasis
- dna binding
- walled carbon nanotubes